卒中替代工作流程的药物经济学影响
本研究为2017年5月至2018年2月的回顾性队列,在初级卒中中心急诊科纳入50例接受静脉阿替普酶(tPA)治疗的急性缺血性卒中成人患者,新流程组与旧流程组各25例。新流程包括床旁配制tPA并将多余药液在中心药房回收。新流程组从25例患者中回收阿替普酶605 mg,估计每年节约成本超过12万美元。新流程组平均门-针时间(52 min vs 60 min;p=0.01)和中位门-针时间(50 min vs 58 min;p=0.03)均统计学上更快。作者认为该多学科模式在初步数据中带来显著成本节约并缩短门-针时间。
要点
- 新流程组从25例患者中回收阿替普酶605 mg,估计每年节约成本超过12万美元。
- 新流程组平均门-针时间52 min vs 旧流程组60 min(p=0.01),中位门-针时间50 min vs 58 min(p=0.03)。
- 新流程为床旁配制tPA并将多余药液在中心药房回收,未影响门-针给药时间。
- 研究为单中心回顾性队列,每组25例,作者称其为初步数据。
- 适用人群为急诊科接受静脉tPA治疗的急性缺血性卒中成人(>18岁)患者。
适用人群与场景
- 急诊科接受静脉阿替普酶(tPA)治疗的急性缺血性卒中成人(>18岁)患者,为连续患者的便利样本。
处置流程与药物剂量
- 新流程:床旁配制tPA,并将多余药液在中心药房回收。
研究设计与关键结果
- 研究类型为回顾性队列,时间2017年5月至2018年2月,在初级卒中中心急诊科进行,共纳入50例患者(新流程组25例,旧流程组25例)。
- 主要终点:新流程组从25例患者中回收阿替普酶605 mg,估计每年节约成本超过12万美元。
- 关键次要终点:新流程组平均门-针时间52 min vs 旧流程组60 min(p=0.01);中位门-针时间50 min vs 58 min(p=0.03)。
证据类型、等级与局限
- 证据类型:回顾性队列(作者称其为初步数据、试点研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,采用多学科模式进行tPA给药可带来显著的成本节约并缩短总体门-针时间。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: The objective of this study was to evaluate a new multidisciplinary process in which intravenous alteplase (tPA) waste, used for acute ischemic stroke (AIS), was salvaged in an attempt to maximize cost effectiveness without impacting door-to-needle (DTN) administration times.
DESIGN: This was a retrospective cohort between May 2017 and February 2018. The primary endpoint evaluated for this study was the total tPA salvaged and total cost savings in U.S. dollars. Secondary endpoints evaluated included overall DTN time in minutes.
SETTING: Emergency department of a primary stroke center.
PATIENTS: A convenience sample of sequential adult (>18 years) patients who received tPA in the ED for AIS were included for analysis.
INTERVENTIONS: New stroke process which involved bedside mixing of tPA and salvaging of excess waste in the main central pharmacy.
MEASUREMENTS AND MAIN RESULTS: A total of 50 patients were included in the final analysis. There were 25 patients included in the new process and old process groups respectively. A total of 605 mg of alteplase was salvaged from 25 patients in the new process group which was associated with an estimated cost savings of over $120,000 annually. Patients in the new process group had statistically faster average (52 min vs. 60 min; p = 0.01) and median (50 min vs. 58 min; p = 0.03) DTN administration times.
CONCLUSION: Preliminary data, in this pilot study, utilizing a multidisciplinary model for tPA administration led to significant cost savings of tPA and decreases in overall DTN administration times.
参考来源
- Gilbert BW, Huffman JB, Slechta J, et al. Pharmacoeconomic impact of an alternative workflow process for stroke. Am J Emerg Med. 2018. PMID: 30442431. doi:10.1016/j.ajem.2018.10.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。